Generic placeholder image

Current Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 0929-8673
ISSN (Online): 1875-533X

99mTc-Radiolabelled Peptides for Tumour Imaging: Present and Future

Author(s): C. Bolzati, F. Refosco, A. Marchiani and P. Ruzza

Volume 17 , Issue 24 , 2010

Page: [2656 - 2683] Pages: 28

DOI: 10.2174/092986710791859388

Price: $65

Abstract

Receptor-binding peptides have attracted an enormous interest in targeting molecules for the development of tumour specific radiopharmaceutical compounds. The overexpression of many receptors on human tumour makes such peptide-ligands attractive agents for diagnostic imaging and therapy of cancers. The use of solid-phase peptide synthesis and the availability of a wide range of bifunctional chelating agents for the radiolabelling of bioactive peptides with radionuclides have produced a wide variety of useful radiopharmaceutical molecules. For diagnostic purposes, techenetium- 99m is the ideal radionuclide thanks to its nuclear properties and the availability of a low cost portable generator system.

Keywords: Peptide receptors, radiolabelled peptides, technetium, tumour imaging


Rights & Permissions Print Export Cite as
© 2022 Bentham Science Publishers | Privacy Policy